NFGCM
MRNA icon

Norman Fields Gottscho Capital Management’s Moderna MRNA Stock Holding History

Norman Fields Gottscho Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,169
Closed -$345K – 59
2024
Q3 		$345K Sell
5,169
-130
-2% -$11.9K 0.11% 51
2024
Q2 		$622K Sell
5,299
-400
-7% -$50.6K 0.22% 41
2024
Q1 		$607K Sell
5,699
-85
-1% -$8.57K 0.23% 44
2023
Q4 		$575K Sell
5,784
-4,015
-41% -$338K 0.23% 43
2023
Q3 		$1.01M Sell
9,799
-250
-2% -$27.9K 0.44% 29
2023
Q2 		$1.22M Sell
10,049
-360
-3% -$48K 0.51% 25
2023
Q1 		$1.6M Buy
10,409
+425
+4% +$70.1K 0.71% 24
2022
Q4 		$1.79M Sell
9,984
-520
-5% -$85K 0.83% 22
2022
Q3 		$1.24M Buy
10,504
+3,630
+53% +$551K 0.6% 25
2022
Q2 		$982K Buy
6,874
+2,055
+43% +$294K 0.45% 37
2022
Q1 		$830K Buy
+4,819
New +$811K 0.31% 45

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Norman Fields Gottscho Capital Management's MRNA Position: Q4 2024 in Review

Norman Fields Gottscho Capital Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 5,169 shares — an estimated $345K sold.

Norman Fields Gottscho Capital Management first reported a position in MRNA in Q1 2022 and held it in 11 quarters. The position peaked at $1.79M in Q4 2022. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Norman Fields Gottscho Capital Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Norman Fields Gottscho Capital Management sold 5,169 Moderna shares in Q4 2024, an estimated $345K.
  • Norman Fields Gottscho Capital Management first reported a position in Moderna in Q1 2022 and held it in 11 quarters.
  • Norman Fields Gottscho Capital Management's Moderna position peaked at $1.79M in Q4 2022.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Norman Fields Gottscho Capital Management's 13F filing for Q4 2024, filed 7 Jan 2025.